📰 Wangy Cepharanthine News
Wangy Cepharanthine News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Wangy Cepharanthine. Real-time updates on events, politics, business and more.
February 13, 2023
Toronto, Ontario--(Newsfile Corp. - February 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development
January 31, 2023
Toronto, Ontario--(Newsfile Corp. - January 31, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development
August 19, 2022
Completes qualification of all necessary analytical methodologies to support production of Cepharanthine-2HCL drug substanceClinical trial-scale production of cGMP Cepharanthine-2HCL drug substance scheduled
June 16, 2022
Results show that oral cepharanthine plus paclitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 28, the final day of dosing compared to paclitaxel
October 15, 2021
Cepharanthine reproducibly demonstrates potential as a monotherapy in treating multiple cancers with unsatisfactory treatment optionsIdentified 4 cancer types where cepharanthine provides additive or
May 6, 2021
PharmaDrug” or the “ Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a service agreement with a respected contract research organization (CRO) with deep expertise in preclinical oncology model development and drug testing, to evaluate the Company’s patented enteric-coat...
May 6, 2021
Pharmadrug Inc.: PharmaDrug Initiates Preclinical Study of Cepharanthine to Both Broaden Its Cancer Scope and to Streamline Its Strategy for Esophageal Cancer PharmaDrug" or the " Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a service agreement with a respected contract rese...